Interstitial photodynamic therapy has a number of potential advantages over superficial treatment. We have treated 50 subcutaneous and cutaneous tumours interstitially, in nine patients. An additional 22 tumours in the same patients, were treated by superficial PDT. Patients received 1.5 -2.0 mg kg of polyhaematoporphyrin and 72 h later underwent treatment using a copper vapour dye laser producing red light at 630 nm.
Photodynamic therapy (PDT) generally involves the systemic administration of a photosensitiser that is retained with some selectivity in tumour tissue when compared with the normal tissue from which the tumour arose (Gomer et al., 1979; Tralau et al., 1987) . The drug is then photoactivated by light of the appropriate wavelength and this leads to localised tumour necrosis which is primarily consequent to vascular collapse (Henderson et al., 1985; Star et al., 1986) . It can be applied safely after other modalities of treatment such as radiation or chemotherapy (Dougherty, 1984; . The results of clinical studies demonstrate that superficial therapy can be very effective for small superficial tumours (Dougherty, 1984; Kato et al., 1986; Parrish, 1983; Robinson et al., 1988; Unsold et al., 1990) and that interstitial therapy shows promise for the treatment of small tumours, but should also allow treatment of non-superficial tumours (Barr et al., 1990; Monnier et al., 1990) .
One of the major disadvantages of current PDT, especially of relevance to superficial treatment, relates to the poor penetration of red light at 630 nm. Previous studies have shown that the optical penetration depth (l/e or 37% level) in tumours, ranges from 1-3 mm (Svaasand, 1984) , 2.7-4.5 mm (Wilson, 1986) and more recently in vivo measurements in human breast tumours 2.9-4.7 (Driver et al., 1991) . Photoactivation can occur at greater depths than this and effective penetration of up to 1 cm can be achieved (Dougherty, 1984; . Newer drugs activated at longer wavelengths offer the potential to improve the penetration depths by a few millimetres, but are not likely to extend it much beyond this.
Interstitial therapy, using multiple fibres, should enable tumours of much larger volumes to be effectively treated and by delivering the light to the point of interest, limit the volume of normal tissue irradiated. Also, by reducing the incident light dose to the skin surface, it should decrease the incidence of skin necrosis, which is a feature of superficial therapy. In animal tumour systems interstitial PDT has been shown to be superior to superficial PDT (Marijnissen et al., 1989) . We have previously shown that plane cut fibres are unsatisfactory for interstitial PDT , because of thermal effects (Feather et al., 1990) at the fibre tip and that diffusing fibres are the fibres of choice for interstitial PDT.
The aims of this study were to investigate interstitial PDT using cylindrical diffusing fibres. To identify response criteria in respect of light and drug doses for tumour and normal tissue effects, determine the volume of tumour that could be successfully treated interstitially and to compare interstitial treatment with superficial therapy in relation to its efficacy and examine the equivalence of light dose from these two methods of light delivery.
Patients and methods
Between November 1988 and January 1990 nine patients aged 46-79 (mean 66) were treated, two of whom were re-treated, photodynamic therapy. All had received prior treatment with radiotherapy and often chemotherapy. Five had adenocarcinomas of the breast, three squamous carcinoma of the lung and one squamous carcinoma of the pinna. All had either cutaneous or subcutaneous metastases or a mixture of both. Fifty tumours were treated using purely interstitial techniques with cylindrical diffusing fibres. Twenty additional tumours in these same patients were treated by superficial photodynamic therapy and the response data accumulated were used to compare light dose equivalence with matched tumours treated by interstitial PDT. All tumours were carefully measured in three dimensions using vernier calipers and allowed tumour volumes to be calculated.
Patients were all treated as in-patients. The cylindrical diffusing fibres were manufactured individually (Feather et al., 1989) , and were calibrated to the appropriate power density for treatment using an integrating sphere prior to insertion in the tumour. Dose was specified in J cm-2 for superficial PDT (Feather et al., 1990) .
Forty-three tumours with volumes of 0. (Parrish, 1983) . It is also assumed that the light is effectively absorbed within a depth of 0.5-0.7 cm. A dose in J cm-3 is thus derived which can then be compared with light delivered interstitially. Treatments were well tolerated with no clinically significant photosensitivity. All areas of skin necrosis have healed and normal tissue healing occured without obvious scar formation within 2-3 months. Tumour responses were commonly rapid and evident within the first week. Figure 1 illustrates the placement techniques used for treatment of the largest tumour and sequential healing of a large area of necrosis consequent to complete tumour lysis.
Plasma porphyrin levels on treatment day (72 h) were 1.8 ytg ml -' ± 0.7 for patients who received 1.5 mg kg-' PHP and 3.4 pg ml -± 1.1 in those receiving 2.0 mg kg'-. Results of porphyrin analysis in plasma and biopsy material are shown in Table I . Although the numbers of these biopsies are small the tumour: normal tissue (skin) ratios are 1.1: 1.0 and therefore do not show much tumour selectivity.
Light and drug dose responses The complete response rate for 50 tumours treated interstitially was 26/50 = 52% (Table II) . A 10% response at 1.Smgkg-PHP, 63% at 2.Omgkg-' and 81% in those treated at the highest light and drug doses. The overall incidence of eschar formation was 32% (16/50), 38% at 2.0mgkg-' PHP and 63% in those treated at the highest light and drug doses (Table III) and was 62% when expressed as a percentage of lesions producing a complete response. No eschars were seen in lesions that did not produce a complete response. No lesion that produced a complete response was seen to recur at the treated site during the period of follow up in any patient. Table IV examines the results of single nodules treated with one fibre in order to ascertain a volume that can be successfully treated using a single fibre. A higher response was seen at doses greater than 100 J cm-3 for tumours less than 1.0 cm3: 18/31 (58%), compared to those treated with light doses of less than lOOJ cm-3 or tumours with volumes greater than 1.0 cm3: 4/12 (33%). It should be stressed, however, that using multiple fibres, in excess of 60 cm-3 of tumour have been successfully treated. Figure 2 shows the relationship between tumour volume and total delivered light dose in joules.
Comparisons between superficial and interstitial PDT Table V examines the doses of light required to achieve complete responses in tumours of comparable dimensions treated by either superficial or interstitial PDT. It is extremely difficult to obtain such information clinically and although these data were obtained from a larger light dose response study it is not implicit that the quoted doses represent the threshold for complete response. Had lower light doses been delivered to individual tumours the same tumour response may have ensued. It is appreciated that this attempt to compare the equivalence of light doses can only be verified by in vivo measurements both within the tumour and at normal tissue/tumour boundaries; These measurements can complicate an otherwise simple treatment, are usually invasive, and by increasing local haemorrhage may interfere with the therapeutic outcome, and hence they may have been counterproductive in such a dose exploratory study.
In vivo light dosimetry In six tumours, a short calibrated detector fibre was placed at the base of the tumour throughout the duration of treatment.
In these cases the tumours were spherical and measured approximately 0.5 cm-2. The energy fluence rate measured at this point should equate to that received at the skin surface, as the treatment fibre was equidistant from the skin and the detector fibre. Although at the base of the tumour some of the signal is due to backscattered light from below whereas at the skin some light is lost. A biopsy of an untreated nodule was used to provide a best estimate of photosensitiser concentration in the irradiated lesion. Light = 185.24 -ratio of plasma: tumour not corrected). The product of light and drug should allow reciprocal comparisons to be made between the relative contributions of light and drug doses. 57.0 J cm2 with a plasma porphyrin 1.06 1g ml-', produced a partial response in another patient (Drug x Light = 60.4), although this patient apparently had a very high tumour porphyrin level (14.15 ng mgi). However, a light dose of 132.9 J cm-2 with a plasma porphyrin of 2.0 jig ml-' (Drug x Light = 265.8), in the third patient, produced no change in the overall dimensions of the tumour but 3 x 1 cm of necrosis on CT measurements. These are amongst the first such attempts to derive true photodynamic dose in terms of the product of porphyrin dose and light fluence and the discrepancies are indicative of the difficulties involved in the accurate determination of such data.
Discussion
These data, although limited, do not provide much evidence of true tumour specificity in terms of drug localisation. Our analysis represents a total porphyrin concentration and does not determine anything about the distribution of porphyrin within the tumour. Achieving selective tumour destruction must therefore depend on differential normal tissue healing, differential distribution of light between tumour and normal tissue and differential photodegradation.
Healing of skin eschars and areas of ulceration, even when extensive, were remarkable supporting the different mechanisms of tissue injury related to PDT in distinction to thermal, Nd:YAG laser (Castro et al., 1983; or radiation damage. This difference would appear to be a consequence of the preservation of subcutaneous collagen allowing healing to occur by regeneration rather than by scarring, and remains one of the most advantageous aspects of clinical PDT treatments .
Although tumour destruction is a function of the porphyrin/light product it has not been our experience, that lower drug dose and higher light doses, or the converse, can achieve as satisfactory complete response rates as higher drug and light doses. Reciprocity of drug and light dose has been shown in experimental animal systems except when drug doses were reduced below a threshold value (Fingar & Henderson., 1987; Cowled & Forbes., 1985) .
Previous measurements of the energy fluence at the eschar edge in patients undergoing superficial therapy showed a mean of 86 ± 31 J cm-2 (16 Observations) (Driver, 1990) . The interstitial results from Patient PT suggest a threshold for both eschar formation and tumour response between 75 J cm-2 and 101 J cm-2. However the patient NL responded to lower doses of light, with a complete response at 36 J cm2, despite a lower porphyrin level in tumour and plasma. No cohesive pattern emerges in the values obtained in patients treated with multiple fibres and it is not possible at present from these measurements to deduce a general fluence at which tumour response can be assured. Our data suggests that satisfactory response rates occur with 2.0 mg kg-i PHP and with light doses in excess of 100 J cm-3 and that a complete response rate of 81% is achievable for small tumours with doses greater than 500 J cm-3. Very large tumours (60 cm-3) can be completely lysed by the use of multiple fibres appropriately placed within it. Clearly many more measurements of energy fluence at critical points are required before definitive conclusions can be drawn. (Freitas, 1986; Levendag et al., 1988; . We have previously established that the penetration depth of red light (630 nm) was 4 mm in human breast cancer patients (Driver et al., 1991) . In this study we have occasionally noted necrosis at much greater distances than would be predicted. In two patients skin necrosis occurred at 16.5 and 8.75 mm from treatment fibres; an experience reported by others (Barr et al., 1990 Complete responses occurred at lower comparable light doses for superficial than for interstitial PDT (Table V) . There are a number of difficulties when comparing superficial PDT with interstitial PDT (McKenzie, 1985) and the figures quoted do not take into account the distributional differences between the two forms of treatment. Superficial therapy is delivered to the tumour with a margin of normal tissue. Interstitial therapy is centred within the tumour delivering less light to the adjacent tumour supporting normal tissues, especially the vasculature and thus exerts a lesser tumour bed effect. The presence and significance of, a tumour bed effect in PDT, is not proven. An increase in tumour response with increasing field size, using superficial treatment in experimental systems (Gilson et al., 1990) and shielding experiments indicate that a certain amount of normal tissue damage is necessary to obtain tumour control (Fingar & Henderson, 1987) . Incident light on the skin surface will fall off exponentially in tissue, after up to 50% of the light has been reflected (Parrish, 1983) ; so that light delivered superficially is inhomogeneously distributed in tissue compared to interstitial therapy, where all the delivered dose should be, effectively, completely absorbed (i.e.: very little is scattered out) by the tissues. Interstitial therapy is obviously invasive and invevitably leads to blood surrounding the fibre. Haemoglobin is likely to be a strong absorber of light even at this wavelength and may therefore reduce the amount of light reaching the perimeter of the tumour. Hence a compensatory higher light dose is required to be isoequivalent. These factors may help explain the results seen clinically. However the success of interstitial therapy gives hope that this treatment may be applied curatively to a wider range of malignancy with efficacy and safety (Ash & Brown, 1989) . It has been demonstrated that with care high complete response rates are possible and that large volumes can be effectively treated. Whether it is desirable to treat such large tumours with PDT is debatable, it is rare that such tumours would occur in the absence of metastatic disease, technically these are laborious and time consuming procedures and as with interstitial brachytherapy PDT is more likely to find a role in the treatment of small volume disease. The clinical role for interstitial PDT has still to be evaluated but photodynamic therapy does have potential advantages over ionising radiation and such a treatment may thus find as useful a place in cancer treatment as interstitial radiotherapy and could be extended to further anatomical sites.
